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Summary and Implications 
Vaccination of swine with an alphavirus-derived 
replicon particle vaccine stimulates a non-specific immune 
response.  This effect was seen when animals were 
challenged with PRRSV at 24 hours post-vaccination.  
Animals that received vaccine had reduced viremia as 
measured by quantitative RT-PCR when compared to 
placebo.  These results highlight the potential of replicon 
particle vaccines to induce robust immune responses in 
swine. 
 
Introduction 
 Porcine reproductive and respiratory syndrome virus 
(PRRSV) is the most economically significant viral 
pathogen of swine in the United States.  Current control 
measures and vaccines have significant drawbacks.  
Enhanced understanding of host immunity is necessary to 
develop more effective vaccines and therapeutics.  
Alphavirus-derived replicon particles (RP) are single-cycle, 
propagation-defective viral vectors.  Numerous studies in a 
wide range of species have demonstrated the safety and 
efficacy of RP as a vaccine platform.  In addition to vaccine 
antigen expression, RP have been used to deliver cytokines, 
such as Interleukin-12 and Type I interferon.  Other 
investigators have demonstrated that RP enhance innate 
immune responses following administration. 
Our group is developing veterinary vaccines utilizing RP 
technology.  One vaccine candidate under development 
expresses the hemagglutinin gene from swine influenza 
virus H3N2 (H3-RP).  The H3-RP was chosen to examine 
the possible anti-PRRSV effects of RP vaccines using a 
young pig challenge model. 
 
Materials and Methods 
Study 1 
Three-week-old pigs (n=12) were obtained from a 
commercial herd historically free of PRRSV and swine 
influenza virus.  Pigs were randomized into groups of six 
animals, and housed together in BSL-2 animal facilities.  At 
approximately four weeks of age, pigs were injected with 
either H3-RP or vaccine diluent (placebo).  The titer of H3-
RP was determined to be 1x10
9
 RP/dose by 
immunofluorescence assay.  Challenge occurred 24 hours 
post-treatment via intranasal inoculation with 2x10
5
 TCID50 
PRRSV in a 2 ml volume.  Pigs were monitored for clinical 
signs and bled periodically for 21 days post-challenge.  
Serum samples were assayed for PRRS viral RNA by 
quantitative real-time RT-PCR (Applied Biosystems).  
 
Study 2 
Three-week-old pigs (n=18) were obtained from the same 
source as in Study 1 and randomized into groups of six 
animals.  At approximately four weeks of age, two groups 
of pigs were injected with H3-RP either 72 hours or 24 
hours prior to challenge.  The third group received vaccine 
diluent as a placebo.  H3-RP formulation and challenge 
material administration was the same as in Study 1.  Clinical 
observation, blood collection, and qRT-PCR were 
conducted as in Study 1. 
 
Results and Discussion 
Study 1 
All animals had detectable viral RNA in serum by three 
days post-challenge, indicating successful challenge.  
Compared to placebo, animals treated with H3-RP had 
significantly lower qRT-PCR titers at 10, 14, and 17 days 
post-challenge when compared to placebo. 
 
Study 2 
All animals became qRT-PCR positive by three days post-
challenge, as in Study 1.  Animals treated with H3-RP at 24 
hours pre-challenge had a statistically significant reduction 
in qRT-PCR titers at 14 days post-challenge when compared 
to placebo.  No other time points or treatments reached 
statistical significance in the qRT-PCR assay. 
 
These results suggest that the immune response stimulated 
by H3-RP vaccination is effective at reducing PRRSV 
viremia in a young pig challenge model.  This effect appears 
to be transient, and is likely due to the host response to the 
virus-like RP.  Additional studies are needed to characterize 
the specific pathways involved in anti-PRRSV innate 
immune responses. 
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